Why is Anagrelide a second-line drug?

Anagrelide (Anagrelide) is usually regarded as a second-line drug for the treatment of idiopathic Thrombocytopenic Purpura (, ITP). Here are a few reasons why anagrelide is classified as a second-line drug:

1.Sequence of use: First-line treatment usually includes oral steroids (such as prednisone) and immunosuppressants (such as dexamethasone, cyclosporine, etc.). These drugs have been widely used and have a long clinical history in controlling thrombocytosis and preventing bleeding. Anagrelide is generally reserved as an alternative option in the event of failure or intolerance of first-line therapy.

2.Side effects and safety: Although anagrelide is an effective antiplatelet drug, it may cause a series of side effects, including adverse reactions in the cardiovascular system, digestive system, nervous system and blood system. Due to its side effects and safety concerns, anagrelide was considered for use only after failure of first-line treatment.

3.Clinical evidence and experience: Compared with first-line therapeutic drugs, anagrelide has relatively little clinical evidence and research support. Although anagrelide has shown efficacy in patients withITPin some studies, its long-term efficacy and safety still require further study

It should be emphasized that second-line drugs do not mean that anagrelide is less effective or unimportant. It may be an effective and appropriate treatment option in certain patient groups. However, first-line therapeutic drugs are well-proven in controlling the condition and preventing complications, and generally have broader clinical applications and richer research support.

When treating essential thrombocythemia (ITP), selection of an appropriate treatment strategy should be based on the patient's condition, medical history, clinical manifestations, and other relevant factors. Doctors will decide whether to use anagrelide as a second-line treatment option based on comprehensive evaluation and develop an individualized treatment plan to achieve optimal efficacy and safety.

Anagrelide has not yet been marketed in China, so patients cannot purchase it domestically and need to purchase the drug through overseas channels. Anagrelide only has the original drug. Outside the mainland, there is the Hong Kong version of the original drug and the foreign Turkish original drug. The price is around 1280 yuan.